Spectral AI shares are trading higher after the company announced that its DeepView SnapShot Wound Imaging System was marked for use in the U.K. and received Class 1 medical device classification with the FDA.
Portfolio Pulse from Benzinga Newsdesk
Spectral AI's shares are trading higher following the announcement that its DeepView SnapShot Wound Imaging System has been approved for use in the U.K. and received Class 1 medical device classification from the FDA.
October 19, 2023 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spectral AI's stock is trading higher due to the approval of its DeepView SnapShot Wound Imaging System in the U.K. and its Class 1 medical device classification from the FDA.
The approval of Spectral AI's DeepView SnapShot Wound Imaging System in the U.K. and its Class 1 medical device classification from the FDA are significant regulatory milestones. These approvals can potentially open up new markets and increase the company's revenue, which is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100